HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

ABT-925

Networked: 3 relevant articles (0 outcomes, 2 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyrimidines: 510
    - ABT-925: 3
  - Piperazines: 26
    - ABT-925: 3

Experts

1.	Abel, S J: 1 article (04/2013)
2.	Bhathena, A: 1 article (04/2013)
3.	Holley-Shanks, R R: 1 article (04/2013)
4.	Idler, K B: 1 article (04/2013)
5.	Katz, D A: 1 article (04/2013)
6.	Kraft, J B: 1 article (04/2013)
7.	Redden, L: 1 article (04/2013)
8.	Robieson, W Z: 1 article (04/2013)
9.	Spear, B: 1 article (04/2013)
10.	Wang, Y: 1 article (04/2013)

Related Diseases

1.

Schizophrenia (Dementia Praecox)

04/01/2011 - "This double-blind, randomized, placebo-controlled, escalating-dose, parallel-group study assessed the efficacy and safety of ABT-925 in the treatment of patients with acute exacerbation of schizophrenia. "
02/01/2013 - "ABT-925, the first selective D(3) receptor antagonist, was recently studied in patients with schizophrenia. "
04/09/2013 - "DNA samples (N=117) were collected in a proof-of-concept, double-blind, randomized, placebo-controlled study of ABT-925 (50 or 150 mg QD) in acute exacerbation of schizophrenia. "
04/01/2011 - "A double-blind, randomized, placebo-controlled study of the dopamine D₃ receptor antagonist ABT-925 in patients with acute schizophrenia."
04/09/2013 - "ABT-925, a selective dopamine D3 receptor (DRD3) antagonist, was tested in schizophrenia. "

Related Drugs and Biologics

1.	Dopamine (Intropin)
2.	DNA (Deoxyribonucleic Acid)
3.	Dopamine D3 Receptors